Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9 ... - Marketscreener.com
LUCD Stock | USD 0.79 0.02 2.60% |
About 55% of Lucid Diagnostics' shareholders are presently thinking to get in. The analysis of overall sentiment of trading Lucid Diagnostics stock suggests that some investors are interested at this time. The current market sentiment, together with Lucid Diagnostics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lucid Diagnostics stock news signals to limit their universe of possible portfolio assets.
Lucid |
Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9 ... Marketscreener.com
Read at news.google.com
Lucid Diagnostics Fundamental Analysis
We analyze Lucid Diagnostics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lucid Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lucid Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Lucid Diagnostics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Lucid Diagnostics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lucid Diagnostics stock to make a market-neutral strategy. Peer analysis of Lucid Diagnostics could also be used in its relative valuation, which is a method of valuing Lucid Diagnostics by comparing valuation metrics with similar companies.
Peers
Lucid Diagnostics Related Equities
FNA | Paragon 28 | 1.86 | ||||
NPCE | Neuropace | 1.10 | ||||
KIDS | Orthopediatrics Corp | 0.91 | ||||
LUNG | Pulmonx Corp | 0.83 | ||||
SRDX | SurModics | 0.10 | ||||
ITGR | Integer Holdings | 0.42 | ||||
OFIX | Orthofix Medical | 0.72 | ||||
LIVN | LivaNova PLC | 1.17 | ||||
NARI | Inari Medical | 1.35 | ||||
ELMD | Electromed | 1.47 | ||||
IRMD | Iradimed | 3.31 | ||||
XAIR | Beyond Air | 4.08 | ||||
CVRX | CVRx | 4.25 | ||||
CLPT | Clearpoint Neuro | 6.52 |
Complementary Tools for Lucid Stock analysis
When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |